biostudies-literatureBryushkova EAMinistry of sciencee0273340https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401152biostudies-literatureUnknown17(8)<h4>Objective</h4>The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (netakimab), anti-IL-6R (tocilizumab), or JAK1/JAK2 inhibitor (baricitinib) or with a standard-of-care therapy alone.<h4>Methods</h4>The observational cohort study included 154 adults hospitalized between February and August, 2020 with RT-PCR-confirmed SARS-CoV-2 with National Early Warning Score2 (NEWS2) < 7 and C-reactive protein (CRP) levels ≤ 140 mg/L on the day of the start of the therapy or observation. Patients were divided into the following groups: I) 4 mg baricitinib, 1 or 2 times a day for an averagePloS oneTocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.PMC9401152075-15-2020-807Mutovina ZYFomina DSLukyanov SAKruglova TSTkacheva ONAkopyan AAChudakov DMBryushkova EAZagrebneva AISkatova VDStrazhesko IDLysenko MAfalseTocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.<h4>Objective</h4>The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (netakimab), anti-IL-6R (tocilizumab), or JAK1/JAK2 inhibitor (baricitinib) or with a standard-of-care therapy alone.<h4>Methods</h4>The observational cohort study included 154 adults hospitalized between February and August, 2020 with RT-PCR-confirmed SARS-CoV-2 with National Early Warning Score2 (NEWS2) < 7 and C-reactive protein (CRP) levels ≤ 140 mg/L on the day of the start of the therapy or observation. Patients were divided into the following groups: I) 4 mg baricitinib, 1 or 2 times a day for an average2022-01-01T00:00:00Z20222026-06-01T02:20:43.823Z2025-04-05T15:17:36.165ZS-EPMC94011523600157610.1371/journal.pone.0273340